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ANEMIA AND CHRONIC KIDNEY DISEASE
Anemia is common among patients with chronic kid-
ney disease (CKD) and is a powerful risk factor for
cardiovascular disease [1–9]. The risk for developing ane-
mia is several times higher in those with CKD as com-
pared to the general United States population [9], and
recent evidence indicates that anemia develops earlier
in CKD than previously thought, especially in diabetic
nephropathy [5]. The cause of anemia in CKD is multi-
factorial, including erythropoietin deficiency, decreased
responsiveness to erythropoietin, shortened red blood
cell survival, iron deficiency, and chronic inflammation
[10]. Observational studies indicate that anemia in CKD
is associated with increased risk for coronary artery dis-
ease [11], hospitalization for cardiac disease [12], death
from congestive heart failure (CHF) [2], and all-cause
mortality [1, 12, 13].
Anemia is a modifiable risk factor in patients with
CKD; however, several studies indicate that treatment
of anemia in the predialysis and dialysis populations is
suboptimal [6, 7, 14, 15]. Cardiac disease at onset of
dialysis is common, including concentric and eccentric
left ventricular hypertrophy (LVH) in 75%, coronary
artery disease in 15%, overt systolic dysfunction in 15%,
and dysrhythmia in 7% [3]. Erythropoietin deficiency
plays a major role in anemia and treatment with exoge-
nous erythropoietin can completely correct anemia in
many with CKD. Treatment of anemia has been associ-
ated with improvement in quality of life in CKD patients
before and after initiation of dialysis [16]. In addition,
treatment of anemia improves hemoglobin level and
quality of life and has been shown to reduce progression
of LVH. However, clinical erythropoietin treatment to
normalize hemoglobin in patients on dialysis has not dem-
onstrated reduction in mortality or morbidity [17, 18].
Thus, treatment with erythropoietin to improve anemia
has not been shown to definitively reduce cardiovascular
mortality or improve cardiac function in those with pre-
existing cardiac disease. Little is known about the effects
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of anemia on cardiovascular disease in CKD or the effects
of treatment on cardiovascular and renal outcomes in CKD
patients prior to initiation of dialysis. The ever-growing
population of CKD patients [19], together with the prev-
alence of anemia and its associated consequences, indi-
cates that additional studies on the impact of anemia
and its treatment in this population are urgently needed.
CONTRIBUTION OF ANEMIA TO
CARDIOVASCULAR DISEASE IN
CHRONIC KIDNEY DISEASE
Cardiovascular disease is the leading cause of death
in patients with CKD and mortality is 30 to 50 times
higher among hemodialysis patients as compared to age-
matched normal subjects [16]. The highest cardiovascu-
lar morbidity and mortality rates occur among type 2
diabetics with nephropathy and point to an increasingly
close relationship between nephropathy and risk for end-
stage renal disease (ESRD) and death [10, 20, 21]. Pro-
spective observational studies in hemodialysis patients
reveal that anemia is associated with increased risk for
cardiac dilatation, cardiac failure, LVH, and cardiovas-
cular death [22–26]. Also, anemia is associated with in-
creased risk for death and hospitalization in elderly pa-
tients with CHF, and treatment of anemia improves
functional capacity and left ventricular function in pa-
tients with CHF with or without CKD [27, 28].
CHF is common in patients with CKD, and anemia is
known to cause heart failure. Heart failure induced by
anemia results in decrease in renal blood flow, tissue
hypoxia, tachycardia, and activation of the sympathetic
nervous system and the renin-angiotensin system. Subse-
quent renal sodium retention leads to volume expansion,
increased venous return, and increased venomotor tone.
These adaptive mechanisms may conspire to induce
worsening renal function and volume overload in those
with CKD. Treatment of anemia with erythropoietin
in CKD patients with clinical CHF is associated with
improvement in cardiac and renal function, as well as
exercise capacity and improved quality of life [25].
Recent studies indicate that LVH is common in CKD
patients, even in early stages of the disease [29]. Retro-
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spective analyses indicate that left ventricular mass re-
gression is associated with increased survival on dialysis,
but this has not been shown in a prospective study [26].
Among many risk factors common to both renal and
cardiovascular disease, anemia has not been carefully
studied as a pathophysiologic mechanism of kidney dis-
ease progression and cardiovascular disease. The high
prevalence of anemia in CKD patients in association
with a high rate of cardiovascular disease and mortality
suggests that a low hemoglobin level may link the two.
Anemia prevalence is up to 10-fold higher among diabet-
ics with CKD and CHF compared to those with CKD
or diabetes alone. This finding suggests that anemia is a
major modifiable risk factor for CHF, particularly among
diabetics [9]. Observational data also point to anemia as
a death risk multiplier among older individuals with
CKD and CHF [30]. Levin et al [31] reported that, in
CKD patients prior to dialysis, both systolic hypertension
and anemia were identified as independent risk factors
for left ventricular wall growth. Importantly, systolic
blood pressure and hemoglobin were shown to confer
similar risk increase for LVH. Specifically, for each 0.5
g/dL decline in hemoglobin there was a 32% increase in
risk for LVH, whereas for every 15 mm Hg increase in
systolic blood pressure there as a 36% increase in risk
for LVH during the 12 month follow-up interval. Addi-
tionally several studies have demonstrated that treatment
of anemia with erythropoietin regresses LVH [32, 33].
In a small study by Hayashi [33] involving 9 patients
with CKD and LVH, complete, but not partial, normal-
ization of hematocrit with erythropoietin treatment re-
gressed pre-existing LVH.
CONTRIBUTION OF ANEMIA TO
PROGRESSION OF CHRONIC
KIDNEY DISEASE
Anemia may also contribute to progression of CKD
[34]. Animal models of renal ablation, hypertension,
and diabetes demonstrated that treatment of anemia
worsened systemic and glomerular hypertension and
renal structural and functional damage [35, 36]. By con-
trast, recent observational studies in diabetics and non-
diabetics indicate that anemia is associated with devel-
opment and progression of kidney disease [37, 38].
Prospective clinical trials indicate that treatment of ane-
mic CKD patients with erythropoietin does not worsen,
and may slow, progression of kidney disease [39, 40–49].
However, limitations of these trials include retrospective
design, small numbers of enrollees, short-term follow up,
surrogate markers of renal outcome, and diverse causes
of kidney disease. Moreover, many of these studies were
designed for safety reasons, not to examine the effect of
anemia treatment on renal outcome. Only one prospec-
tive, randomized trial of partial correction of anemia
Fig. 1. Hypothetical mechanisms by which anemia may cause chronic
kidney disease.
actually demonstrated a beneficial effect on progression
of kidney disease [41].
Analysis of the Reduction in Endpoints in NIDDM with
the Angiotensin II Antagonist Losartan (RENAAL)
study, hemoglobin at baseline was identified as an inde-
pendent predictor for progression of the combined renal
end point of doubling serum creatinine and ESRD in
patients with type 2 diabetes and nephropathy [50]. In
a preliminary report, Mohanram et al [51] found that
baseline hemoglobin in the RENAAL trial was an inde-
pendent predictor for ESRD.
WHY WOULD ANEMIA CAUSE PROGRESSION
OF CHRONIC KIDNEY DISEASE?
Anemia in CKD could accelerate progression of kid-
ney disease by at least two mechanisms: (1) renal tissue
hypoxia; and (2) cardiac failure (Fig. 1). These mecha-
nisms are not mutually exclusive, thus both could con-
tribute to progression of renal disease. Even if renal
blood flow to the kidney is normal, relative tissue hypoxia
could worsen renal structure and function, leading to
renal fibrosis, decline in glomerular filtration rate, and
further worsening of anemia.
It is known that both the renal cortex and medulla
are relatively hypoxic under normal circumstances [52].
Worsening hypoxia in the renal medulla in the setting
of anemia may result in more severe tissue hypoxia and
create a hypoxic environment that sets the stage for
interstitial injury. Recent studies support this hypothesis.
Whole animal and in vitro studies indicate that renal
hypoxia is associated with up-regulation of hypoxia-
inducible factor (HIF) 1 and 2, collagen gene expres-
sion in renal fibroblasts, and up-regulation of metallopro-
teinase 1 [53]. HIF-1 is a transcriptional regulator of
erythropoietin gene, as well as heme oxygenase, nitric
oxide synthases, extracellular matrix, and apoptosis
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genes that is up-regulated during chronic renal hypoxia
[54]. Up-regulation of HIF-1 and 2 occurs in chroni-
cally ischemic rat kidneys and is associated with inter-
stitial fibrosis [55, 56]. In addition, anemia may alter
glomerular function by induction of increased renal sym-
pathetic nerve activity, causing preferential efferent va-
soconstriction with increased glomerular pressure and
proteinuria [57, 58]. It has been hypothesized that ane-
mia-induced renal sympathetic activation could mediate
increased proteinuria, leading to progression of CKD by
this hemodynamic mechanism [58]. Unfortunately, there
are no human studies examining the impact of anemia
or its treatment on measurement of renal function in
anemic CKD patients.
CURRENT TREATMENT GOAL FOR ANEMIA
IN CKD
Diagnosis and treatment guidelines for anemia have
been published by the National Kidney Foundation [59].
The current guidelines state that anemia can be diagnosed
when hemoglobin is less than 11 g/dL in premenopausal
women and less than 12 g/dL in men and postmenopausal
women. The work-up should include measurement of he-
moglobin, hematocrit, red blood cell indices, serum iron,
iron binding capacity, percent saturation, and stool occult
blood. Target hemoglobin for all CKD patients regardless
of dialysis is 11 to 12 g/dL. The rationale for this range is
the fact that hemoglobin less than 11 g/dL is below normal
for premenopausal women, and a value less than 10 g/dL
is associated with increased mortality risk. However, cur-
rent data indicate that treatment of anemia among CKD
patients is poor. About 70% of patients initiated on
dialysis have anemia and are not treated with erythropoi-
etin, and more than 50% have severe anemia and a
hematocrit level 30%. Taken together, current evi-
dence suggests that educating both nephrologists and
non-nephrologists concerning therapy of anemia in CKD
can be improved and the DOQI guidelines for target
hemoglobin should be re-examined in this light.
CONCLUSION
Anemia is highly prevalent in CKD patients and much
higher than previously thought. Anemia is a modifiable
risk factor for both cardiovascular and renal outcomes.
Treatment of anemia improves quality of life and can
induce regression of LVH. However, studies thus far do
not prove that anemia treatment to any level improves
survival in CKD patients. Future studies of anemia in
chronic kidney disease are needed to further elaborate
the mechanisms of anemia, to determine cause and effect
of anemia and cardiovascular and renal outcomes, to
develop novel methods to measure erythropoiesis, and
novel cardioprotective and neuroprotective effects of
erythropoietin independent of its hematopoietic effect.
Ongoing clinical trials to examine the effect of anemia
correction on cardiovascular and renal outcomes should
provide critical new information to guide practice in the
future.
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